Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
FibroGen Sponsored Study Titled ‘A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05301517
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
FibroGen Q3 EPS $0.54 Up From $0.35 YoY, Sales $156.00M Beat $143.46M Estimate
FibroGen (NASDAQ:FGEN) reported quarterly earnings of $0.54 per share. This is a 54.29 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $156.00
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: